Patent Grant
7666205
The present invention is directed to an inflatable device and method for use in orthopedic procedures to treat bone, and in particular to an improved device and method for reducing fractures in bone and treatment of the spine.
Medical balloons are commonly known for dilating and unblocking arteries that feed the heart (percutaneous translumenal coronary angioplasty) and for arteries other than the coronary arteries (noncoronary percutaneous translumenal angioplasty). In angioplasty, the balloon is tightly wrapped around a catheter shaft to minimize its profile, and is inserted through the skin and into the narrowed section of the artery. The balloon is inflated, typically, by saline or a radiopaque solution, which is forced into the balloon through a syringe. Conversely, for retraction, a vacuum is pulled through the balloon to collapse it.
Medical balloons also have been used for the treatment of bone fractures. One such device is disclosed in U.S. Pat. No. 5,423,850 to Berger, which teaches a method and an assembly for setting a fractured tubular bone using a balloon catheter. The balloon is inserted far away from the fracture site through an incision in the bone, and guide wires are used to transport the uninflated balloon through the medullary canal and past the fracture site for deployment. The inflated balloon is held securely in place by the positive pressure applied to the intramedullary walls of the bone. Once the balloon is deployed, the attached catheter tube is tensioned with a calibrated force measuring device. The tightening of the catheter with the fixed balloon in place aligns the fracture and compresses the proximal and distal portions of the fractured bone together. The tensioned catheter is then secured to the bone at the insertion site with a screw or similar fixating device.
As one skilled in the related art would readily appreciate, there is a continuing need for new and innovative medical balloons and balloon catheters, and in particular a need for balloon catheter equipment directed toward the treatment of diseased and damaged bones. More specifically, there exists a need for a low profile, high-pressure, puncture and tear resistant medical balloon, that can be used to restore the natural anatomy of damaged cortical bone.
The present invention is directed to an inflatable device for use in restoring the anatomy of diseased or fractured bone such as for treatment of the spine. In one embodiment, the inflatable device is a balloon-tipped catheter. The catheter and/or balloon may be varied in size, shape, or configuration according to the desired application. The device may be deployed in any type of bone where collapsed fractures of cortical bone may be treated by restoring the bone from its inner surface. Examples of such bones include, without limitation, vertebral bodies, long bones, the distal radius, and the tibial plateau. Additionally, the inflatable device may also be adapted for use as a spinal prosthesis. For instance, a balloon of the present invention may be designed and configured to replace a vertebral disk, or may serve as a distraction instrument and implant for intervertebral fusion.
The invention is constructed in a manner specialized to restore the anatomy of a fractured bone which has sufficient normal cancellous volume to contain the device. The device is constructed for controlled deployment and reliability at pressures between about 40 to about 400 psi, more preferably at between about 200 to about 300 psi, and most preferably at about 250 psi. The present invention comprises a balloon catheter device in which the inflatable vessel comprises a puncture and tear resistant balloon.
In one embodiment, the inflatable device has a layer of puncture and tear resistant material. In another embodiment, the balloon has multiple layers or coatings of material. The layers or coatings may be applied to achieve a desired shape, feel, performance, or appearance. For instance, layers may be provided to achieve a desired texture, surface characteristic, or color. Examples of surface characteristics include a high or low friction surfaces, and regions of the device capable of providing enhanced gripping to help anchor the device or position it as it is inflated. The outer layer or coating of the inflatable device also may be either hydrophobic or hydrophillic, depending on the degree of “wetability” desired.
In another embodiment, the invention comprises a rigid catheter which allows for the placement and deployment of the balloon tipped catheter without internal structural reinforcement. This provides the catheter with surprising advantages, including improved surgical control over placement of the balloon tip and rotational control over the balloon during deployment.
The shape of the inflatable device and/or catheter may be curved, shaped or otherwise configured to allow for an easier approach to the bone cavity or to correspond to the portion of the bone which is to be restored. In one embodiment, an axial balloon is constructed with a uniform bulge and blunt distal end to allow the deployment of the balloon against the wall of the prepared bone cavity, and to facilitate uniform expansive pressure in the cavity when inflated. In another embodiment, an offset balloon of circular cross section is employed, while another embodiment uses an offset balloon with a non-circular cross section. In another embodiment, the balloon may be curved to correspond to the interior wall of the cortical bone. In yet another embodiment, a shape memory catheter is used to better position the inflatable device within right or left bones, or in the left or right side of bones that possess a sagittal plane of symmetry.
One embodiment uses a plurality of offset balloons on a single catheter. Deployment and deflation of the balloons can be varied according to the surgical procedure performed by the surgeon. In one embodiment, the plurality of balloons are deployed to restore the cortical bone. Then, one or more balloons is selectively deflated so that bone filler material may be injected into the region previously occupied by the balloon. Once the bone filler has sufficiently gelled or hardened in this region, the remaining balloon or balloons similarly may be deflated and the bone filled.
In one embodiment, the region occupied by the deployed balloon is filled with bone filler at the same time that the balloon is being deflated. Preferably, the rate at which the region is filled with bone filler material is approximately the same rate at which the balloon is deflated so that the volume of the treated region within the bone remains approximately the same.
In yet another embodiment, the cavity may be treated with a sealing material prior to or after deployment of the balloon. The use of a sealant may assist in reducing or preventing leakage of filler material from the cavity, or to prevent bone materials or body fluids from leaching into the cavity. Generally, sealants comprising fibrin or other suitable natural or synthetic constituents may be used for this purpose. The sealant materials may be delivered to the cavity walls by spray application, irrigation, flushing, topical application, or other suitable means, including applying sealant materials to the balloon exterior as a coating. The sealant, also, may be placed inside the treated area first, and then an inflatable device may be used to push the sealant outward toward the cavity walls.
Additionally, the bone cavity may be irrigated and/or aspirated. Irrigation media may comprise saline, water, antibiotic solution or other appropriate fluids to wash the bony interior and release debris. Aspiration of the bone cavity may be used to help clear the bone cavity of bony debris, fatty marrow, and blood products that may prevent adequate dispersal of filler material or that may constrict the cavity. Each of the steps of applying a sealant, irrigating and aspirating may be considered optional, and may be performed after inflation of the balloon, or before, or not at all.
The invention also relates to a method for reducing bone fractures comprising forming a cavity within a damaged bone, inserting the inflatable device into the cavity, inflating the device so that it restores collapsed or deteriorated portions of the cortical bone, preferably returning the bone approximately to its natural anatomy. In a preferred embodiment, a cavity is created in the portion of the bone in which the device is to be deployed and inflated. In one embodiment, the cavity is irrigated before the device is inserted into the bone in order to remove bone marrow and cancellous bone from the area where the device will be inflated. The inflatable device is inserted into the bone and positioned so that inflation of the balloon will assist in restoration of the cortical bone. Once the cortical bone has been sufficiently restored, the balloons may be deflated either in succession or altogether. Bone filler may be added to the region previously occupied by the balloon. Alternatively, the balloon or balloons may be deflated and bone filler injected simultaneously as described in the embodiments above.
In another embodiment, the inflatable device may remain inside the patient for an extended period after the surgical procedure is completed. In one embodiment, the inflatable device remains inside a treated bone. The inflatable device also may be adapted for disk replacement. An inflatable device for disk replacement may be designed to be biologically resorbable while leaving filler material in place or may remain indefinitely. The present invention may be further adapted for use as a distraction device and synthetic allograft spacer for intervertebral fusion.
Preferred features of the present invention are disclosed in the accompanying drawings, wherein similar reference characters denote similar elements throughout the several views, and wherein:
In the description that follows, any reference to either orientation or direction is intended primarily for the convenience of description and is not intended in any way to limit the scope of the present invention thereto.
The balloon 30 may be used to treat any bone with an interior cavity sufficiently large enough to receive the balloon 30. Non-limiting examples of bones that are suitable candidates for anatomical restoration using the device and method of the present invention include vertebral bodies, the medullary canals of long bones, the calcaneus and the tibial plateau. The balloon 30 can be designed and adapted to accommodate particular bone anatomies and different cavity shapes, which may be made in these and other suitably large bones.
Additionally, the balloon may be designed and configured to be deployed and remain in the bone cavity for an extended period of time. For instance, the balloon may be inflated with natural or synthetic bone filler material or other suitable inflation fluid once the balloon is located within the bone cavity. Once filled, the balloon is allowed to remain within the bone for a prescribed period or perhaps indefinitely. The duration of time that the balloon remains within the bone may depend upon specific conditions in the treated bone or the particular objective sought by the treatment. For example, the balloon may remain within the cavity for less than a day, for several days, weeks, months or years, or even may remain within the bone permanently. As explained in greater detail below, the balloon may also be adapted to serve as a prosthetic device outside of a specific bone cavity, such as between two adjacent vertebrae.
In addition, the outer surface of the balloon may be treated with a coating or texture to help the balloon become more integral with the surrounding bone matter or to facilitate acceptance the balloon by the patient. The selection of balloon materials, coatings and textures also may help prevent rejection of the balloon by the body. The inner surface of the balloon likewise may be textured or coated to improve the performance of the balloon. For instance, the inner surface of the balloon may be textured to increase adhesion between the balloon wall and the material inside.
In yet another embodiment, the balloon may be designed to rupture, tear or otherwise open after the filler material injected inside the balloon has set up or sufficiently gelled, cured or solidified. The balloon may then be removed from the bone while leaving the filler material inside. This approach may result in a more controlled deployment of bone filler material to a treated area. It also may allow the bone filler material to be at least partially preformed before being released into the bone. This may be particularly beneficial where leakage of bone filler material out of damaged cortical bone may be a concern, although there may be other situations where this configuration would also be beneficial.
Alternatively, the balloon may be opened or ruptured in a manner that would permit the filler material to allow the inflation fluid to be released into the cavity. For instance, the opening of the balloon may be predetermined so that the flow of filler material travels in a desired direction. Moreover, the filler material may be held within the balloon until it partially sets so that, upon rupture of the balloon, the higher viscosity of the filler material limits the extent to which the filler material travels.
The balloon also may be designed and configured to release inflation fluid into the cavity in a more controlled fashion. For instance, the balloon catheter might be provided with a mechanism to initiate the rupture process in a highly controlled fashion. In one embodiment, predetermined seams in the balloon might fail immediately and rupture at a certain pressure. In another embodiment, the seams might fail only after prolonged exposure to a certain pressure, temperature, or material.
One skilled in the art would appreciate any number of ways to make the balloon open or rupture without departing from the spirit and scope of the present invention. For example, at least a portion of the balloon may be dissolved until the filler material is released into the bone cavity. In another example, the balloon may rupture and become harmlessly incorporated into the inflation fluid medium. In yet another example, the filler material may be designed to congeal when contacted to a chemical treatment applied to the surface of the balloon. In yet another embodiment, two balloons (or a single balloon having two chambers) may be designed and configured to release a combination of fluids that when mixed together react to form an inert filler material within the cavity. In another embodiment, different areas of the seam or balloon might be designed to rupture at different predetermined pressures or at different times.
Further, the balloon may be designed to be opened in any number of ways. For instance, a surgeon may lyse the balloon once the desired conditions of the bone filler material are reached. A balloon adapted to rupture and release inflation fluid into direct contact with a cavity also may be designed and configured to split along predetermined seams. The seams might run parallel to the longitudinal axis of the balloon and remain secured to the catheter at the proximal tip of the balloon, resembling a banana peel which has been opened. In another embodiment, the predetermined seams might consist of a single spiraling seam originating form the distal tip of the balloon and ending at the proximal tip of the balloon, resembling an orange peel which has been opened.
Other balloon adaptations may be provided to lyse the balloon in a controlled fashion. For instance, a balloon may be constructed with failure zones that are adapted so that structural failure under a triggering condition would occur preferentially in a localized area. For instance, a balloon might have a failure zone comprising a thinner membrane. In another example, the balloon might be designed to lack tensile reinforcing elements in a particular region. In yet another example, a region of the balloon might be comprised of a material that would fail due to a chemical reaction. For instance, the chemical reaction may be an oxidation or reduction reaction wherein the material might sacrificially neutralize a weak acid or base. In another example, the sacrificial region might comprise a pattern of pore like regions. This sacrificial region may comprise a specific pattern of pores that might form a latent perforation in the balloon membrane or may be randomly distributed in a localized area.
The ruptured balloon may then be removed from the bone cavity, leaving behind the deployed bone filler material. To facilitate removal of the ruptured balloon from the bone cavity, the balloon may be treated with special coating chemicals or substances or may be textured to prevent the balloon from sticking to the filler material or cavity walls. In one embodiment, the balloon might open at the distal end. This configuration may allow the balloon to be more readily removed from the bone cavity after the balloon has opened or ruptured.
Also, biologically resorbable balloons may be designed and configured according to the present invention. For instance, a deployed balloon comprising bio-resorbable polymers might be transformed by physiological conditions into substances which are non-harmful and biologically compatible or naturally occurring in the body. These substances may remain in the patient or be expelled from the body via metabolic activity. In one example, a balloon designed to restore the anatomy of a vertebral body would be placed within a prepared cavity inside the treated vertebra and inflated with a radio-opaque filler material. Immediately after inflation (or after the filler material has partially set), the balloon may be disengaged, separated, or detached from the catheter to remain within the bone. As the balloon resorbs new bone may replace the filler material. Alternatively, the filler material may be converted by biological activity into bone or simply remain in the bone.
As one skilled in the art would readily appreciate a deployed balloon may be designed for partial or complete resorption. For instance, a selectively resorbable balloon may be configured to produce a bio-inert implant, structure, or a configuration comprising a plurality of such entities. For example, a balloon may have a resorbable membrane component and a biologically inert structural reinforcing component. In another example, a balloon designed to be selectively resorbable might form a series of bio-inert segments. These bio-inert segments might provide structural containment, or a reinforcing interface at weakened portions of the cortical bone. The segments may also be designed to cooperate and beneficially dissipate post operative stresses generated at the interface between the restored cortical bone and filler material. The precise nature of the stress reduction may be adapted to a particular anatomy.
An implanted balloon may also be designed such that it can be resorbed only after certain conditions are met. For instance, a balloon designed to provide containment in a particular region of unhealthy or damaged cortical bone may eventually be resorbed following one or more triggering conditions. In one example, the return of normal physiological conditions would trigger the break down of the balloon implant. The triggering condition may involve relative temperature, pH, alkalinity, redox potential, and osmotic pressure conditions between the balloon and surrounding bone or cancellous materials.
In another example, a controlled chemical or radiological exposure would trigger the break down of the balloon. For instance, a chemically triggered resorption may include, without limitation, a physician prescribed medicament or specially designed chemical delivered to the balloon via oral ingestion or intravenous injection. An electrical charge or current, exposure to high frequency sound, or X-rays may also be used to trigger biological resorption of the balloon.
Resorbable balloons may also provide an implanted balloon with beneficial non structural properties. For instance, soluble compounds contained within a bio-resorbable sheath may have particular clinical benefits. For example, a resorable balloon may break down when healthy cancellous bone remains in contact with the balloon for about six weeks. The breakdown of the balloon may then expose a medicament placed within the balloon structure as an internal coating. Also, the medicament may be incorporated into the balloon matrix itself to provide a time release function for delivering the medicament. The medicament may promote additional bone growth, generally, or in a particular area. Examples of other such complementary benefits include, without limitation, antibacterial effects that prevent infection and agents that promote muscle, nerve, or cartilaginous regeneration.
In use, the balloon 30 is inserted into a bone cavity that has been prepared to allow the balloon to be placed near the damaged cortical bone. Preferably, the cancellous tissue and bone marrow inside the bone and in the area to be treated may be cleared from the region in advance of deploying the balloon. Clearing the treated region may be accomplished by either shifting or relocating the cancellous bone and marrow to untreated regions inside the bone, or alternatively by removing the materials from the bone. Alternatively, cancellous bone and marrow may be cleared with a reamer, or some other device.
Additionally, the bone cavity may be irrigated and/or aspirated. Preferably, the aspiration would be sufficient to remove bone marrow within the region to be restored. In particular, a region as big as the fully deployed balloon should be aspirated in this manner. More preferably, a region exceeding the extent of the fully deployed balloon by about 2 mm to 4 mm would be aspirated in this manner. Clearing the cavity of substantially all bone marrow near or within the treated region may prove especially useful for restoring the bone and incorporating the balloon as a prosthetic device to remain in the cavity.
Clearing substantially all bone marrow from the treated area also may provide better implant synthesis with the cortical bone, and prevent uncontrolled displacement of bone marrow out of areas of damaged cortical bone. For example, a balloon for restoring a vertebral body may further comprise a prosthetic implant which will remain in the restored vertebrae for an extended period of time. Removing substantially all the bone marrow from the region of the vertebrae to be restored might provide better surface contact between the restored bone and the implant.
One skilled in the art would readily appreciate the clinical benefits for preventing the release of marrow or bone filling material to the vascular system or the spinal canal. For example, removing substantially all the bone marrow from the treated region of the bone may reduce the potential for inadvertent and systemic damage caused by embolization of foreign materials released to the vascular system. For vertebral bodies, removing the bone marrow may also reduce the potential for damaging the spinal cord from uncontrolled displacement during deployment of the balloon or a subsequent compression of the vertebrae and implant mass.
Further, the cavity may be treated with a sealant to help prevent or reduce leakage of filler material from the cavity or to help prevent bone materials or body fluids from leaching into the cavity. Generally, sealants comprising fibrin or other suitable natural or synthetic constituents may be used for this purpose. The sealant may be applied at any suitable time or way, such as by spray application, irrigation, flushing, topical application. For example, the sealant may be spray coated inside the cavity prior to or after deployment of the balloon. In addition, the sealant may be applied to the balloon exterior as a coating so that the sealant would be delivered to the cavity as the balloon is deployed.
In another example, the sealant may be placed inside the treated area first, and then an inflatable device may be used to push the sealant outward toward the cavity walls. The inflatable device may be rotated or moved axially in order to apply the sealant. Also, the balloon may not be fully pressurized or may be gradually pressurized while the sealant is being applied.
The viscosity or other properties of the sealant may be varied according to the type of delivery and the procedure used. For example, it is preferred that the sealant is a gel if it is placed inside the cavity and the balloon is used to apply it to the cavity walls. As previously described, each of these optional steps regarding the use of a sealant may be performed after inflation of the balloon, or before, or not at all.
Thereafter, the balloon 30 is inserted into the prepared cavity, where it is inflated by fluid, (e.g., saline or a radiopaque solution) under precise pressure control. Preferably, the balloon 30 is inflated directly against the cortical bone to be restored, by an inflation device 15. In this manner, the deployed balloon presses the damaged cortical bone into a configuration that reduces fractures and restores the anatomy of the damaged cortical bone.
Following fracture reduction, the balloon is deflated by releasing the inflation pressure from the apparatus. Preferably, the balloon may be further collapsed by applying negative pressure to the balloon by using a suction syringe. The suction syringe may be the inflation device itself, or an additional syringe, or any other device suitable for deflating the balloon. After the balloon is sufficiently deflated, the balloon may be removed from the cavity, and the bone cavity may be irrigated or aspirated. Optionally, the cavity also may be treated with a sealant. The cavity then can be filled with bone filler material. The bone filler material may be natural or synthetic bone filling material or any other suitable bone cement. As previously described, each of these optional steps may be performed after inflation of the balloon, or before, or not at all.
As described more fully below, the timing of the deflation of the balloon and the filling of the cavity with bone filler material may be varied. In addition, the balloon may not be deflated prior to completing the surgical procedure. Instead, it may remain inside the bone cavity for an extended period. Thus, the method of the present invention relates to creating a cavity in cancellous bone, reducing fractures in damaged cortical bone with a medical balloon, restoring the natural anatomy of the damaged bone, and filling the restored structure of the bone with filling material.
The inflatable device may also be adapted to serve as a prosthetic device outside of a bone. One example is that the balloon may be used as an artificial disk located between two adjacent vertebrae. The use of an inflatable device in this manner may allow for replacement of the nucleus of the treated disk, or alternatively may be used for full replacement of the treated disk. Portions of the treated disk may be removed prior to deploying the inflatable device. The amount of disk material removed may depend upon the condition of the treated disk and the degree to which the treated disk will be replaced or supported by the inflatable device. The treated disk may be entirely removed, for instance, when the inflatable device serves as a complete disk replacement. If the inflatable device will serve to support or replace the nucleus or other portion of the treated disk, then less material, if any, may need to be removed prior to deployment.
The construction and shape of the inflatable device may vary according to its intended use as either a full disk replacement or a nuclear replacement. For instance, an inflatable device intended to fully replace a treated disk may have a thicker balloon membrane or have coatings or other treatments that closely replicate the anatomic structure of a natural disk. Some features include coatings or textures on the outer surface of the inflatable device that help anchor it or bond it to the vertebral endplates that interface with the artificial disk. The balloon membrane also may be configured to replicate the toughness, mechanical behavior, and anatomy of the annulus of a natural disk. The filler material likewise may be tailored to resemble the mechanical behavior of a natural disk.
In another example, if the inflatable device is intended to treat only the nucleus of the disk, the balloon may be designed with a thin wall membrane that conforms to the interior of the natural disk structures that remain intact. In addition, the balloon membrane may be resorbable so that the filler material remains after the inflatable device has been deployed. Alternatively, the balloon membrane may be designed and configured to allow the balloon to be lysed and removed from the patient during surgery. One advantage of this design would be that the balloon may function as a delivery device that allows interoperative measurement of the volume of the filler material introduced into the patient. In addition, this design allows for interoperative adjustment of the volume, so that filler material can be added or removed according to the patient's anatomy before permanent deployment. Other design features of the inflatable device and filler material described herein for other embodiments or uses also may be utilized when designing a balloon as an artificial disk.
In one embodiment of an artificial disk, the balloon is inflated with a radio-opaque material to restore the natural spacing and alignment of the vertebrae. The inflating solution or material may be cured or reacted to form a viscous liquid or deformable and elastic solid. Preferably, such a balloon may comprise an implant possessing material and mechanical properties which approximate a natural and healthy disk. For instance, the balloon may be designed for long term resistance to puncture and rupture damage, and the filler material may be designed and configured to provide pliable, elastic, or fluid like properties. Generally, filler material for a replacement disk balloon may comprise any suitable substance, including synthetic and bio-degradable polymers, hydrogels, and elastomers. For example, a balloon may be partially filled with a hydrogel that is capable of absorbing large volumes of liquid and undergoing reversible swelling. A hydrogel filled balloon may also have a porous or selectively porous containment membrane which allows fluid to move in and out of the balloon as it compressed or expanded. The filler material may also be designed and configured to form a composite structure comprising a solid mass of materials.
Balloons of the present invention also may be adapted for use as a distraction instrument and an implant for interbody fusion, such as for the lumbar or cervical regions. For instance, a inflatable device of the present invention may be used for posterior lumbar interbody fusion (PLIF). A laminotomy, for example, may be performed to expose a window to the operation site comprising a disc space. The disc and the superficial layers of adjacent cartilaginous endplates may then be removed to expose bleeding bone in preparation for receiving a pair of PLIF spacers. A balloon of the present invention may then be inserted into the disk space and inflated to distract the vertebrae. The controlled inflation of the balloon may ensure optimum distraction of the vertebrae and facilitate maximum implant height and neural for aminal decompression. Fluoroscopy and a radio-opaque balloon inflation fluid may assist in determining when a segment is fully distracted.
If the balloon is to serve as a distraction instrument, a bone or synthetic allograft along with cancellous bone graft or filler material may then be implanted into contralateral disc space. Once the implant and other materials are in the desired position, the balloon may be deflated and removed from the disk space and a second implant of the same height may be inserted into that space.
If the balloon is to serve as a spacer for intervertebral body fusion, the balloon may be inflated with a filler material that sets to form an synthetic allograft implant in vivo. Once the implant has been adequately formed, the balloon may be lysed and removed from the disk space. In another example, the inflated balloon is left intact and is separated from the catheter to remain within the disk space as a scaffold for new bone growth. As previously described, a balloon implant also may be resorbed by physiological conditions and expelled from the patient or transformed and remodeled into new bone growth.
For techniques involving multiple deployments of balloons or filler material, different radiographic signatures may be used for each deployment to enhance the quality of fluroscopic imagery and to assist the surgeon in interpreting spacial relationships within the operation site. The use of different radiographic signatures may be used, for example, with inflatable devices when they are used as instruments (such as a bone restoration tool or as a distraction device), when they are used to deliver bone filler material, or when they are used as implants. Additionally, the use of different radiographic signatures may be utilized for multiple deployment of filler material. For instance, a technique involving the deployment of two balloons between adjacent vertebrae might benefit from such an approach. Similarly, other orthopedic procedures, such as vertebroplasty, also may involve the deployment of multiple balloons having different radiographic signatures. In another example, when the balloon of the present invention is used as a PLIF spacer, the filler material within the first of two intervertebral spacer implant balloons may be provided with less radio-opacity then the second implant. As one skilled in the art would readily appreciate, varying the radio-opacity of the respective implants would facilitate fluoroscopic monitoring and deployment of the second implant. In particular, this would prevent a deployed implant on a first side from blocking the fluoroscopic image of a second implant. This advantage may also be realized when differing radiographic signatures are used in any situation involving multiple deployments, such as for multiple deployments of balloons or filler materials as described above.
The radio-opacity of each implant may be varied by incorporating different concentrations of a radio-opaque material within the filler material which inflates the balloon. For example, filler materials comprising two different concentrations of barium sulfate may be used. Similarly, different radio-opaque materials having distinguishable flouroscopic characteristics may be used.
A composite balloon comprising at least two materials that may serve as a reinforcing component and as a boundary forming component. The boundary forming component may be any suitable material used for forming a balloon. Examples of such materials are described more fully herein. The reinforcing component may provide added tensile strength to the balloon by picking up tensile stress normally applied to the boundary forming component of the balloon. The reinforcing component may be designed and configured to distribute these forces evenly about its structure, or may be designed and configured to form a space frame for the deployed balloon structure. The reinforcing component may facilitate better shape control for the balloon and provide for a thinner boundary forming component.
In one embodiment the reinforcing member component may be a braided matrix extending over selected areas of the balloon. In another embodiment, the braided matrix may enclose the balloon structure in its entirety. In another embodiment, braided matrix is on the inside of the boundary forming component of the balloon. Conversely, in another embodiment the braided matrix is located on the outside of the boundary forming component of the balloon. In one embodiment, the braided matrix is located within the boundary forming component. For example, a boundary forming component comprising a membrane might include a braided matrix within the membrane. The reinforcing strength of the braided matrix may be influenced by the type of material from which it is constructed, or by the shape and dimension of the individually braided reinforcing members.
Additionally, the reinforcing strength of the braided matrix may be determined by the tightness of the weave. For example, a more dense pattern for the braided matrix might provide greater strength but less flexability, than a less dense weave of a similar pattern. Also, different patterns may have different combinations of physical characteristics. The angle of the intersecting braided members may also be varied to optimize the physical properties of the balloon. The braided matrix may therefore be customized to provide a certain combination of physical or chemical properties. These properties may include tensile and compressive strength, puncture resistance, chemical inertness, shape control, elasticity, flexability, collapsability, and ability to maintain high levels of performance over the long term. The braided materials may be comprised of any suitable material including nitinol, polyethylene, polyurethane, nylon, natural fibers (e.g., cotton), or synthetic fibers. One firm which manufactures braided matrices of the type described above is Zynergy Core Technology.
As noted above the boundary forming component may comprise a synthetic membrane formed from polyurethane or other materials as described for the general balloon construction. The membrane may be coated on the exterior to enhance non-reactive properties between the balloon and the body, or to ensure that a balloon will not become bonded to the balloon inflation materials. Thus, a lysed balloon may be withdrawn without significant disturbance to the filled cavity. It is expected that a balloon formed from a membrane and braided matrix may designed to operate at an internal pressure of about 300 psi.
As previously described, the size and configuration of the inflation device may vary according to the particular bone to be restored.
As described in Table 1, a preferred balloon for a vertebral body would have tubing 60 with outer diameter D1 that ranges from about 1.5 mm to about 3.0 mm. The tubing 60 preferably would also be suitable for attachment to a 16 gauge catheter. As best shown in
The preferred embodiments described above include preferred sizes and shapes for balloons comprising a braided matrix and membrane. As previously noted such a balloon may be adapted to remain with a vertebral body, as a prosthetic device or implant.
Similarly, the balloon may have a combination of uniform and curved lengths comprising the tapered end of the balloon. The tapered end also may be unsymmetrical about the central axis of the balloon. A balloon comprising a braided matrix and membrane components may be of particular use in developing balloons having a tapered end or unsymmetrical geometry because the braided material can be used to improve shape control or create a space frame for the deployed balloon.
Similarly, the balloon styles depicted in
Referring to
As described in Table 2, the following exemplary embodiments are primarily directed toward vertebral bodies. In one embodiment, the total length L10 is about 20 mm, the working length L11 is about 15 mm, the horizontal distance L12 of the tapered distal end is about 3 mm, and the outer diameter D6 of the circular bulge is about 6 mm. In another embodiment, the balloon has similar dimensions except that the outer diameter D6 is about 8 mm. In yet another embodiment, the balloon diameter D6 is about 12 mm.
As described in Table 3, the following exemplary embodiment is primarily directed toward vertebral bodies. In one embodiment, the total length L13 is about 20 mm, the working length L14 is about 15 mm, and the horizontal distance L15 of the tapered distal end is about 3 mm. Further, the vertical height L16 and the lateral width L17 of the balloon 145 are 14 mm and 14 mm, respectively.
Referring to
In yet another exemplary embodiment of a complex balloon,
In addition, length L25 and length L26 of the U-rod 185 preferably extend beyond the distal edge 200 of the balloon deployment opening 170 to provide a suitable anchoring length L27 for the U-rod 185 within the catheter 165. U-rod segment lengths L25 and L26 need not be equal. The rounded tip 205 of the U-rod 185 may be fully recessed or may partially extend from the proximal end 175 of the catheter 165. In one embodiment, the tip 205 of the U-rod 185 is secured to the catheter 165 by a soldered, brazed or welded connection. A glued fastener or other attachment means may also be used. For instance, a snap together fastening method may be used. Depending on the number of balloon deployment openings 170 and the material of catheter 165 construction, the number of reinforcing rods 185 will vary. Also, the means for joining a plurality of reinforcing rods 185 together and connecting the reinforcing rods 185 to the catheter 165 may vary from the embodiments shown.
In addition, multiple rods may be used instead of a U-rod to accommodate a reinforced catheter with a plurality of balloon deployment openings. One skilled in the art would readily appreciate that one particular geometry of reinforcing rods may prove easiest to manufacture, assemble, or configure. Therefore, one embodiment may prove to be the most cost effective solution for a particular balloon configuration. For this reason, these embodiments are not intended to be a complete set of cross sections contemplated by the invention, rather general illustrations of the reinforcing rod concept. TABLE 4 presents general dimensions for the catheter depicted in
Reinforcing elements, alternatively, may be individual rails which are connected to and oriented around the catheter perimeter by a plurality of spacer rings which are mounted on an internal lumen. The reinforcing elements may further be wire elements that are post tensioned at the distal tip of the catheter. For this reason, the relative sizing of the balloon deployment window, the catheter strips and the reinforcing elements may be reconfigured to accommodate a particular anatomical, mechanical, therapeutic, or clinical need.
For example,
In yet another embodiment, shown in
As shown further in
One skilled in the art would readily appreciate that more apertures may be used as appropriate to effect the desired rate of fluid transfer, and that a folded multi-chamber balloon may be simple to assemble and test during manufacturing. Thus, creating complex balloons from a folded multi-chamber balloon 250 embodiments may also provide cost savings.
Similarly,
While the above invention has been described with reference to certain preferred embodiments, it should be kept in mind that the scope of the present invention is not limited to these embodiments. The balloon can be modified or extended to accommodate particular formulations of balloon construction materials or fabrication techniques which may require multiple layers with different relative locations one to another (e.g., placing one layer on the outside and a second layer on the inside.) Similarly, the number and spacing of the balloon openings in the catheter and the reinforcing method may be changed to better implement the window deployment of one or more inflatable structures. Also, balloons with dimple forming projections may be produced to the extent they do not impede significantly ultimate balloon performance. Different balloon materials and surface coatings, or outer layers of different materials or surface coatings may also be applied to the balloon to facilitate a smaller balloon profile. The embodiments above can also be modified so that some features of one embodiment are used with the features of another embodiment. One skilled in the art may find variations of these preferred embodiments which, nevertheless, fall within the spirit of the present invention, whose scope is defined by the claims set forth below.
This application is a continuation of application Ser. No. 09/908,899, filed Jul. 20, 2001 now U.S. Pat. No. 6,632,235, which claims the benefit under 35 U.S.C. §119(e) of Provisional Application No. 60/284,510, filed Apr. 19, 2001. The entire content of these applications is expressly incorporated herein by reference thereto.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2381050 | Hardinge | Aug 1945 | A |
| 2426535 | Turkel | Aug 1947 | A |
| 3648294 | Shahrestani | Mar 1972 | A |
| 3701703 | Zimmer et al. | Oct 1972 | A |
| 3741204 | Thiele | Jun 1973 | A |
| 3800788 | White | Apr 1974 | A |
| 3866248 | Kummer | Feb 1975 | A |
| 3867728 | Stubstad et al. | Feb 1975 | A |
| 3875595 | Froning | Apr 1975 | A |
| 4018230 | Ochiai et al. | Apr 1977 | A |
| 4055029 | Kalbow et al. | Oct 1977 | A |
| 4200939 | Oser | May 1980 | A |
| 4213461 | Pevsner | Jul 1980 | A |
| 4274163 | Malcom et al. | Jun 1981 | A |
| 4313434 | Segal | Feb 1982 | A |
| 4327736 | Inoue | May 1982 | A |
| 4369772 | Miller | Jan 1983 | A |
| 4399814 | Pratt, Jr. et al. | Aug 1983 | A |
| 4448195 | LeVeen et al. | May 1984 | A |
| 4462394 | Jacobs | Jul 1984 | A |
| 4466435 | Murray | Aug 1984 | A |
| 4467479 | Brody | Aug 1984 | A |
| 4488549 | Lee et al. | Dec 1984 | A |
| 4498473 | Gereg | Feb 1985 | A |
| 4562598 | Kranz | Jan 1986 | A |
| 4572186 | Gould et al. | Feb 1986 | A |
| 4595006 | Burke et al. | Jun 1986 | A |
| 4627434 | Murray | Dec 1986 | A |
| 4637396 | Cook | Jan 1987 | A |
| 4653489 | Tronzo | Mar 1987 | A |
| 4686973 | Frisch | Aug 1987 | A |
| 4697584 | Haynes | Oct 1987 | A |
| 4702252 | Brooks et al. | Oct 1987 | A |
| 4706670 | Anderson et al. | Nov 1987 | A |
| 4719918 | Bonomo et al. | Jan 1988 | A |
| 4760844 | Kyle | Aug 1988 | A |
| 4772287 | Ray et al. | Sep 1988 | A |
| 4801263 | Clark | Jan 1989 | A |
| 4820349 | Saab | Apr 1989 | A |
| 4888022 | Huebsch | Dec 1989 | A |
| 4888024 | Powlan | Dec 1989 | A |
| 4892550 | Huebsch | Jan 1990 | A |
| 4896662 | Noble | Jan 1990 | A |
| 4904260 | Ray et al. | Feb 1990 | A |
| 4932969 | Frey et al. | Jun 1990 | A |
| 4932975 | Main et al. | Jun 1990 | A |
| 4941877 | Montano, Jr. | Jul 1990 | A |
| 4969888 | Scholten et al. | Nov 1990 | A |
| 5002576 | Fuhrmann et al. | Mar 1991 | A |
| 5021241 | Yamahira et al. | Jun 1991 | A |
| 5041114 | Chapman et al. | Aug 1991 | A |
| 5059193 | Kuslich | Oct 1991 | A |
| 5071435 | Fuchs et al. | Dec 1991 | A |
| 5087244 | Wolinsky et al. | Feb 1992 | A |
| 5102413 | Poddar | Apr 1992 | A |
| 5108404 | Scholten et al. | Apr 1992 | A |
| 5108438 | Stone | Apr 1992 | A |
| 5112304 | Barlow et al. | May 1992 | A |
| 5120316 | Morales et al. | Jun 1992 | A |
| 5147366 | Arroyo et al. | Sep 1992 | A |
| 5163949 | Bonutti | Nov 1992 | A |
| 5171280 | Baumgartner | Dec 1992 | A |
| 5171297 | Barlow et al. | Dec 1992 | A |
| 5176683 | Kimsey et al. | Jan 1993 | A |
| 5192296 | Bhate et al. | Mar 1993 | A |
| 5192326 | Bao et al. | Mar 1993 | A |
| 5201706 | Noguchi et al. | Apr 1993 | A |
| 5209723 | Twardowski et al. | May 1993 | A |
| 5213580 | Slepian et al. | May 1993 | A |
| 5246421 | Saab | Sep 1993 | A |
| 5264260 | Saab | Nov 1993 | A |
| 5270086 | Hamlin | Dec 1993 | A |
| 5295994 | Bonutti | Mar 1994 | A |
| 5300025 | Wantink | Apr 1994 | A |
| 5303718 | Krajicek | Apr 1994 | A |
| 5324261 | Amundson et al. | Jun 1994 | A |
| 5330429 | Noguchi et al. | Jul 1994 | A |
| 5331975 | Bonutti | Jul 1994 | A |
| 5336178 | Kaplan et al. | Aug 1994 | A |
| 5337734 | Saab | Aug 1994 | A |
| 5338295 | Cornelius et al. | Aug 1994 | A |
| 5338299 | Barlow | Aug 1994 | A |
| 5342301 | Saab | Aug 1994 | A |
| 5344459 | Swartz | Sep 1994 | A |
| 5358486 | Saab | Oct 1994 | A |
| 5364357 | Aase | Nov 1994 | A |
| 5370614 | Amundson et al. | Dec 1994 | A |
| 5383929 | Ledergerber | Jan 1995 | A |
| 5390683 | Pisharodi | Feb 1995 | A |
| 5411477 | Saab | May 1995 | A |
| 5423824 | Akerfeldt et al. | Jun 1995 | A |
| 5423850 | Berger | Jun 1995 | A |
| 5443496 | Schwartz et al. | Aug 1995 | A |
| 5443781 | Saab | Aug 1995 | A |
| 5456665 | Postell et al. | Oct 1995 | A |
| 5460608 | Lodin et al. | Oct 1995 | A |
| 5466222 | Ressemann et al. | Nov 1995 | A |
| 5466262 | Saffran | Nov 1995 | A |
| 5468245 | Vargas, III | Nov 1995 | A |
| 5480400 | Berger | Jan 1996 | A |
| 5492532 | Ryan et al. | Feb 1996 | A |
| 5499973 | Saab | Mar 1996 | A |
| 5514153 | Bonutti | May 1996 | A |
| 5533987 | Pray et al. | Jul 1996 | A |
| 5549679 | Kuslich | Aug 1996 | A |
| 5550172 | Regula et al. | Aug 1996 | A |
| 5556382 | Adams | Sep 1996 | A |
| 5562736 | Ray et al. | Oct 1996 | A |
| 5569195 | Saab | Oct 1996 | A |
| 5569219 | Hakki et al. | Oct 1996 | A |
| 5571189 | Kuslich | Nov 1996 | A |
| 5591234 | Kirsch | Jan 1997 | A |
| 5599301 | Jacobs et al. | Feb 1997 | A |
| 5601593 | Freitag | Feb 1997 | A |
| 5624392 | Saab | Apr 1997 | A |
| 5634936 | Linden et al. | Jun 1997 | A |
| 5645597 | Krapiva | Jul 1997 | A |
| 5647848 | Jørgensen | Jul 1997 | A |
| 5653689 | Buelna et al. | Aug 1997 | A |
| 5653760 | Saffran | Aug 1997 | A |
| 5658310 | Berger | Aug 1997 | A |
| 5660225 | Saffran | Aug 1997 | A |
| 5665121 | Gie et al. | Sep 1997 | A |
| 5674295 | Ray et al. | Oct 1997 | A |
| 5693100 | Pisharodi | Dec 1997 | A |
| 5697932 | Smith et al. | Dec 1997 | A |
| 5702410 | Klunder et al. | Dec 1997 | A |
| 5707390 | Bonutti | Jan 1998 | A |
| 5716416 | Lin | Feb 1998 | A |
| 5718707 | Mikhail | Feb 1998 | A |
| 5728063 | Preissman et al. | Mar 1998 | A |
| 5735902 | Li et al. | Apr 1998 | A |
| 5755690 | Saab | May 1998 | A |
| 5755797 | Baumgartner | May 1998 | A |
| 5759173 | Preissman et al. | Jun 1998 | A |
| 5759191 | Barbere | Jun 1998 | A |
| 5772681 | Leoni | Jun 1998 | A |
| 5788703 | Mittelmeier et al. | Aug 1998 | A |
| 5800439 | Clyburn | Sep 1998 | A |
| 5810826 | Akerfeldt et al. | Sep 1998 | A |
| 5820613 | Van Werven-Franssen et al. | Oct 1998 | A |
| 5824087 | Aspden et al. | Oct 1998 | A |
| 5824088 | Kirsch | Oct 1998 | A |
| 5824093 | Ray et al. | Oct 1998 | A |
| 5827289 | Reiley et al. | Oct 1998 | A |
| 5847046 | Jiang et al. | Dec 1998 | A |
| 5849014 | Mastrorio et al. | Dec 1998 | A |
| 5868779 | Ruiz | Feb 1999 | A |
| 5888220 | Felt et al. | Mar 1999 | A |
| 5891090 | Thornton | Apr 1999 | A |
| 5893850 | Cachia | Apr 1999 | A |
| 5902268 | Saab | May 1999 | A |
| 5906606 | Chee et al. | May 1999 | A |
| 5925051 | Mikhail | Jul 1999 | A |
| 5935169 | Chan | Aug 1999 | A |
| 5954728 | Heller et al. | Sep 1999 | A |
| 5961490 | Adams | Oct 1999 | A |
| 5972015 | Scribner et al. | Oct 1999 | A |
| 5976186 | Bao et al. | Nov 1999 | A |
| 5984926 | Jones | Nov 1999 | A |
| 5997582 | Weiss | Dec 1999 | A |
| 6004289 | Saab | Dec 1999 | A |
| 6017305 | Bonutti | Jan 2000 | A |
| 6022369 | Jacobsen et al. | Feb 2000 | A |
| 6022376 | Assell et al. | Feb 2000 | A |
| 6048346 | Reiley et al. | Apr 2000 | A |
| 6063112 | Sgro | May 2000 | A |
| 6066154 | Reiley et al. | May 2000 | A |
| 6096038 | Michelson | Aug 2000 | A |
| 6110210 | Norton et al. | Aug 2000 | A |
| 6110211 | Weiss | Aug 2000 | A |
| 6113603 | Medoff | Sep 2000 | A |
| 6113639 | Ray et al. | Sep 2000 | A |
| 6127597 | Beyar et al. | Oct 2000 | A |
| 6132465 | Ray et al. | Oct 2000 | A |
| 6143013 | Samson et al. | Nov 2000 | A |
| 6179842 | Spotorno et al. | Jan 2001 | B1 |
| 6179856 | Barbere | Jan 2001 | B1 |
| 6186978 | Samson et al. | Feb 2001 | B1 |
| 6187043 | Ledergerber | Feb 2001 | B1 |
| 6187048 | Milner et al. | Feb 2001 | B1 |
| 6193686 | Estrada et al. | Feb 2001 | B1 |
| D439980 | Reiley et al. | Apr 2001 | S |
| 6235043 | Reiley et al. | May 2001 | B1 |
| 6241734 | Scribner et al. | Jun 2001 | B1 |
| 6248110 | Reiley et al. | Jun 2001 | B1 |
| 6248131 | Felt et al. | Jun 2001 | B1 |
| 6280456 | Scribner et al. | Aug 2001 | B1 |
| 6287313 | Sasso | Sep 2001 | B1 |
| D449691 | Reiley et al. | Oct 2001 | S |
| 6306177 | Felt et al. | Oct 2001 | B1 |
| 6332894 | Stalcup et al. | Dec 2001 | B1 |
| 6336930 | Stalcup et al. | Jan 2002 | B1 |
| 6355013 | van Muiden | Mar 2002 | B1 |
| 6356782 | Sirimanne et al. | Mar 2002 | B1 |
| 6375659 | Erbe et al. | Apr 2002 | B1 |
| 6395007 | Bhatnagar et al. | May 2002 | B1 |
| 6395032 | Gauchet | May 2002 | B1 |
| 6402750 | Atkinson et al. | Jun 2002 | B1 |
| 6416776 | Shamie | Jul 2002 | B1 |
| 6423083 | Reiley et al. | Jul 2002 | B2 |
| 6425923 | Stalcup et al. | Jul 2002 | B1 |
| 6428576 | Haldimann | Aug 2002 | B1 |
| 6440138 | Reiley et al. | Aug 2002 | B1 |
| 6443988 | Felt et al. | Sep 2002 | B2 |
| 6447515 | Meldrum | Sep 2002 | B1 |
| 6468279 | Reo | Oct 2002 | B1 |
| 6478800 | Fraser et al. | Nov 2002 | B1 |
| 6558390 | Cragg | May 2003 | B2 |
| 6613054 | Scribner et al. | Sep 2003 | B2 |
| 6620162 | Kuslich et al. | Sep 2003 | B2 |
| 6632235 | Weikel et al. | Oct 2003 | B2 |
| 6663647 | Reiley et al. | Dec 2003 | B2 |
| 6679886 | Weikel et al. | Jan 2004 | B2 |
| 6706069 | Berger | Mar 2004 | B2 |
| 6716216 | Boucher et al. | Apr 2004 | B1 |
| 6719761 | Reiley et al. | Apr 2004 | B1 |
| 6726691 | Osorio et al. | Apr 2004 | B2 |
| 6733532 | Gauchet et al. | May 2004 | B1 |
| 6740093 | Hochschuler et al. | May 2004 | B2 |
| 6863672 | Reiley et al. | Mar 2005 | B2 |
| 6899719 | Reiley et al. | May 2005 | B2 |
| 6981981 | Reiley et al. | Jan 2006 | B2 |
| 7025771 | Kuslich et al. | Apr 2006 | B2 |
| 7044954 | Reiley et al. | May 2006 | B2 |
| 7097648 | Globerman et al. | Aug 2006 | B1 |
| 7153307 | Scribner et al. | Dec 2006 | B2 |
| 7166121 | Reiley et al. | Jan 2007 | B2 |
| 7226481 | Kuslich | Jun 2007 | B2 |
| 7241303 | Reiss et al. | Jul 2007 | B2 |
| 7261720 | Stevens et al. | Aug 2007 | B2 |
| 20010004710 | Felt et al. | Jun 2001 | A1 |
| 20010011174 | Reiley et al. | Aug 2001 | A1 |
| 20010023371 | Bonutti | Sep 2001 | A1 |
| 20010032019 | Van Dyke et al. | Oct 2001 | A1 |
| 20010034527 | Scribner et al. | Oct 2001 | A1 |
| 20010041896 | Reiley et al. | Nov 2001 | A1 |
| 20010044626 | Reiley et al. | Nov 2001 | A1 |
| 20010049527 | Cragg | Dec 2001 | A1 |
| 20010049531 | Reiley et al. | Dec 2001 | A1 |
| 20020013600 | Scribner et al. | Jan 2002 | A1 |
| 20020022856 | Johnson et al. | Feb 2002 | A1 |
| 20020032444 | Mische | Mar 2002 | A1 |
| 20020049448 | Sand et al. | Apr 2002 | A1 |
| 20020058947 | Hochschuler et al. | May 2002 | A1 |
| 20020068974 | Kuslich et al. | Jun 2002 | A1 |
| 20020068975 | Teitelbaum et al. | Jun 2002 | A1 |
| 20020077701 | Kuslich | Jun 2002 | A1 |
| 20020082600 | Shaolian et al. | Jun 2002 | A1 |
| 20020082605 | Reiley et al. | Jun 2002 | A1 |
| 20020082608 | Reiley et al. | Jun 2002 | A1 |
| 20020099384 | Scribner et al. | Jul 2002 | A1 |
| 20020099385 | Ralph et al. | Jul 2002 | A1 |
| 20020123750 | Eisermann et al. | Sep 2002 | A1 |
| 20020161373 | Osorio et al. | Oct 2002 | A1 |
| 20020169471 | Ferdinand | Nov 2002 | A1 |
| 20020188299 | Reiley et al. | Dec 2002 | A1 |
| 20030220649 | Bao et al. | Nov 2003 | A1 |
| 20040073308 | Kuslich et al. | Apr 2004 | A1 |
| 20040097930 | Justis et al. | May 2004 | A1 |
| 20040102774 | Trieu | May 2004 | A1 |
| 20040167625 | Beyar et al. | Aug 2004 | A1 |
| 20040210297 | Lin et al. | Oct 2004 | A1 |
| 20040215343 | Hochschuler et al. | Oct 2004 | A1 |
| 20040215344 | Hochschuler et al. | Oct 2004 | A1 |
| 20040220615 | Lin et al. | Nov 2004 | A1 |
| 20050070911 | Carrison et al. | Mar 2005 | A1 |
| 20050143827 | Globerman et al. | Jun 2005 | A1 |
| 20050234498 | Gronemeyer et al. | Oct 2005 | A1 |
| 20060079905 | Beyar et al. | Apr 2006 | A1 |
| 20060100706 | Shadduck et al. | May 2006 | A1 |
| 20060190083 | Arnin et al. | Aug 2006 | A1 |
| 20060271061 | Beyar et al. | Nov 2006 | A1 |
| 20060293750 | Sherman et al. | Dec 2006 | A1 |
| 20070055266 | Osorio et al. | Mar 2007 | A1 |
| 20070055267 | Osorio et al. | Mar 2007 | A1 |
| 20070055280 | Osorio et al. | Mar 2007 | A1 |
| 20070055284 | Osorio et al. | Mar 2007 | A1 |
| 20070055285 | Osorio et al. | Mar 2007 | A1 |
| 20070282443 | Globerman et al. | Dec 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 198 11 264 | Sep 1999 | DE |
| 0 493 789 | Dec 1991 | EP |
| 2 358 589 | Aug 2001 | GB |
| 02-279165 | Nov 1990 | JP |
| 4-303444 | Oct 1992 | JP |
| 8-98850 | Apr 1996 | JP |
| 11-9618 | Jan 1999 | JP |
| WO 9316664 | Sep 1993 | WO |
| WO 9639970 | Dec 1996 | WO |
| WO 9726847 | Jul 1997 | WO |
| WO 9805377 | Feb 1998 | WO |
| WO 9820939 | May 1998 | WO |
| WO 9856301 | Dec 1998 | WO |
| WO 9908616 | Feb 1999 | WO |
| WO 9929246 | Jun 1999 | WO |
| WO 9937212 | Jul 1999 | WO |
| WO 9951149 | Oct 1999 | WO |
| WO 9962416 | Dec 1999 | WO |
| WO 0009024 | Feb 2000 | WO |
| WO 0128439 | Apr 2001 | WO |
| WO 0134026 | May 2001 | WO |
| WO 0176514 | Oct 2001 | WO |
| WO 0176514 | Oct 2001 | WO |
| WO 0200143 | Jan 2002 | WO |
| WO 0217801 | Mar 2002 | WO |
| WO 0230338 | Apr 2002 | WO |
| WO 0243628 | Jun 2002 | WO |
| WO 03007853 | Jan 2003 | WO |
| WO 2005048856 | Jun 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20040098015 A1 | May 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60284510 | Apr 2001 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09908899 | Jul 2001 | US |
| Child | 10636549 | US |
